Today: 7 February 2026
Subscribe
Browse Category

NYSE:CI News 9 January 2026 - 6 February 2026

Oscar Health (OSCR) stock slips again in premarket as insurer cost fears spread ahead of earnings

Oscar Health (OSCR) stock slips again in premarket as insurer cost fears spread ahead of earnings

Oscar Health shares fell 2.3% to $12.22 in premarket trading Friday after a 5.4% drop Thursday, as investors reacted to Molina Healthcare’s profit warning and exit from Medicare Part D. Molina’s stock plunged nearly 35% after hours, dragging other managed-care stocks lower. Oscar reports earnings Feb. 10, with investors watching for updates on 2026 enrollment and claims.
6 February 2026
·······
Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

Cigna shares rose 3.2% to $280.46 after posting Q4 adjusted earnings of $8.08 per share, above forecasts, though its 2026 outlook missed estimates. Express Scripts agreed to a 10-year FTC settlement on insulin pricing, expected to cut patient costs by up to $7 billion. Evernorth pharmacy revenue jumped 20% to $36.3 billion. Cigna’s board raised its quarterly dividend to $1.56 per share.
5 February 2026
·····
UnitedHealth stock falls again after FTC insulin deal puts OptumRx back in focus

UnitedHealth stock falls again after FTC insulin deal puts OptumRx back in focus

UnitedHealth shares fell nearly 3% to $275.92 in after-hours trading Wednesday after the FTC announced a 10-year insulin pricing settlement with Cigna’s Express Scripts, increasing scrutiny on OptumRx and CVS Caremark. Investors are watching for an FTC oral argument Feb. 5 and a House hearing on drug prices Feb. 11. CVS and Cigna shares also declined. UnitedHealth did not comment.
5 February 2026
·······
UnitedHealth stock price slides 3% as Optum pricing study and FTC pressure keep UNH in focus

UnitedHealth stock price slides 3% as Optum pricing study and FTC pressure keep UNH in focus

UnitedHealth shares fell about 3% Wednesday, closing at $275.58, after a Cornell study linked Optum’s surgery-center acquisitions to an 11% price hike in commercial claims. Investors are watching for Medicare Advantage rate decisions in April amid ongoing regulatory scrutiny of UnitedHealth’s Optum and other managed-care firms.
4 February 2026
······
UnitedHealth stock bounces even after Truist, JPMorgan trim targets as Medicare Advantage rates loom

UnitedHealth stock bounces even after Truist, JPMorgan trim targets as Medicare Advantage rates loom

UnitedHealth shares rose 1% to $289.75 Monday, outperforming peers as Humana, Elevance, and Cigna declined. Truist and JPMorgan cut price targets but kept positive ratings. Investors focused on Medicare Advantage payment rates and 2026 cost trends after last week’s sector sell-off. Final 2027 Medicare Advantage rates are expected in April.
2 February 2026
··········
UnitedHealth stock slips after-hours as PBM fee disclosure rule adds fresh pressure on UNH

UnitedHealth stock slips after-hours as PBM fee disclosure rule adds fresh pressure on UNH

UnitedHealth shares fell 0.6% to $292.29 in after-hours trading Thursday after the U.S. Labor Department proposed new disclosure rules for pharmacy benefit managers. The proposal would require PBMs to reveal fee and compensation details. Investors are also closely watching upcoming Medicare Advantage rate decisions. Related health insurer stocks showed mixed movement late Thursday.
30 January 2026
·······
Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

XLV fell 0.51% to $157.48 Friday, trailing the S&P 500, which ended flat. Health insurer CEOs faced House scrutiny over rising premiums and consolidation, with UnitedHealth pledging ACA rebates in 2026. UnitedHealth reports earnings Jan. 27, Regeneron on Jan. 30. Corcept Therapeutics jumped 45% after positive ovarian cancer trial results.
24 January 2026
········
UnitedHealth stock rises as CEO heads to Congress with Obamacare rebate pledge

UnitedHealth stock rises as CEO heads to Congress with Obamacare rebate pledge

UnitedHealth shares rose 1.8% to $353.85 after the company pledged to rebate 2026 ACA marketplace profits amid scrutiny from lawmakers over affordability. Premiums for ACA plans are set to more than double next year, rising to $1,904, according to KFF. Investors await UnitedHealth’s Jan. 27 earnings report for updates on enrollment and policy risks.
22 January 2026
······
UnitedHealth stock drops today — what traders are watching before UNH earnings

UnitedHealth stock drops today — what traders are watching before UNH earnings

New York, Jan 16, 2026, 11:53 EST — Regular session UnitedHealth Group Incorporated (UNH) shares dipped roughly 1.3% on Friday, closing at $334.40. As the Dow pulled back, the largest health insurer by market cap turned into one of its biggest drags. (MarketWatch) The pullback follows President Donald Trump’s healthcare proposal, unveiled just a day earlier, which would swap government insurance subsidies for direct payments to consumers—a move that could upend the way coverage is bought and priced. Insurer stocks jumped on Thursday after the announcement, though the plan lacks specifics and faces a split Congress. (Reuters) Investors are watching
16 January 2026
·········
UnitedHealth (UNH) stock slips as Senate report puts Medicare Advantage under the microscope

UnitedHealth (UNH) stock slips as Senate report puts Medicare Advantage under the microscope

New York, Jan 13, 2026, 19:13 EST — After-hours Shares of UnitedHealth Group Incorporated dropped nearly 2% Tuesday, deepening a retreat sparked by a U.S. Senate report scrutinizing how the insurer logs diagnoses in Medicare Advantage. Humana, Elevance Health, and Cigna also saw declines. The report comes at a tricky point for the sector. Insurers are pushing to reassure investors they can steady margins following a tough run under government plans, even as lawmakers and regulators ramp up scrutiny on billing and audits. Medicare Advantage is managed by private insurers but funded by the federal government. These plans get a
14 January 2026
······
UnitedHealth (UNH) stock slips as Congress summons CEO; investors eye earnings date

UnitedHealth (UNH) stock slips as Congress summons CEO; investors eye earnings date

New York, Jan 9, 2026, 19:28 EST — After-hours UnitedHealth Group shares fell roughly 0.8% on Friday, lingering around $344 in after-hours trading as U.S. lawmakers intensified scrutiny of major insurers ahead of hearings scheduled for later this month. (stockanalysis.com) The hearings are significant as policy uncertainty is creeping back into managed care valuations. Investors have promptly pushed down the group whenever Washington discusses premiums, subsidies, or regulation. UnitedHealth faces tricky timing. It’s gearing up to update guidance for 2026 just as lawmakers prepare to press the company on costs and coverage issues. Leaders of the House Energy and Commerce
10 January 2026
·······
UnitedHealth stock rises as lawmakers summon insurers; UNH earnings date now in focus

UnitedHealth stock rises as lawmakers summon insurers; UNH earnings date now in focus

New York, Jan 8, 2026, 20:57 (ET) — Market closed U.S. House lawmakers have called on UnitedHealth Group Incorporated (UNH.N) and four other major insurers to testify on coverage affordability later this month, signaling growing Washington scrutiny. UnitedHealth shares rose 1.5% to close at $346.85 on Thursday. The House Energy and Commerce Committee and the Ways and Means Committee extended invitations to UnitedHealth, CVS Health, Cigna, Elevance and Ascendia for testimony on Jan. 22. Reuters The timing is sensitive. Congress is once again locked in a dispute over subsidies under the Affordable Care Act, known as Obamacare, a debate that
9 January 2026
·······
1 2

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Anglo American share price slips as BofA turns neutral after copper outlook cut

Anglo American share price slips as BofA turns neutral after copper outlook cut

7 February 2026
Anglo American shares closed down 0.75% at 3,435 pence Friday after BofA Global Research downgraded the miner to “neutral” and raised its price target to 3,600 pence. Anglo cut its 2026 copper production guidance and warned of continued weakness at De Beers. The company expects $200 million in charges tied to its Chile copper operations in the second half of 2025.
Go toTop